search
Back to results

Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

Primary Purpose

Non Muscular Invasive Bladder Cancer

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
CG0070
n-dodecyl-B-D-maltoside
Sponsored by
CG Oncology, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Muscular Invasive Bladder Cancer focused on measuring high-grade Ta papillary disease, high-grade T1 papillary disease, carcinoma in situ, Bacillus-Calmette-Guerin unresponsive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Have pathologically confirmed World Health Organization (WHO) grading system employed for tumor grading) high-risk NMIBC unresponsive to prior BCG therapy defined as:

Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy

  • Received prior adequate BCG therapy as defined as at least one of the following ("5+2" minimum exposure):

    1. At least five of six doses of an initial induction course (adequate induction) plus at least two of three doses of maintenance therapy, OR
    2. At least five of six doses of an initial induction course (adequate induction) plus at least two of six doses of a second induction course.
  • Ineligible for radical cystectomy or refusal of radical cystectomy
  • Adequate organ function

Key Exclusion Criteria:

  • Muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer
  • Has known upper tract or prostatic urethra malignancy
  • Has systemic anti-cancer therapy, including investigational agents, within 4 weeks of Baseline
  • Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior organ transplant
  • Prior treatment with adenovirus-based cancer therapy
  • Clinically significant or active cardiac disease
  • Active autoimmune disease

Sites / Locations

  • Urology Centers of Alabama
  • BCG Oncology
  • Mayo Clinic Cancer CenterRecruiting
  • Arizona Institute of UrologyRecruiting
  • University of California - IrvineRecruiting
  • American Institute of Research
  • Skyline Urology - Sherman Oaks
  • Skyline Urology - Torrance
  • University of ColoradoRecruiting
  • MedStar HospitalRecruiting
  • Mayo Clinic - JacksonvilleRecruiting
  • Moffit Cancer CenterRecruiting
  • Emory UniversityRecruiting
  • University of KansasRecruiting
  • Chesapeake UrologyRecruiting
  • Mayo RochesterRecruiting
  • Mercy Medical CenterRecruiting
  • New Jersey UrologyRecruiting
  • Our Lady of LourdesRecruiting
  • Montefiore Medical Center
  • StonyBrook Cancer CenterRecruiting
  • Duke UniversityRecruiting
  • Wake Forest UniversityRecruiting
  • University of ToledoRecruiting
  • University of Pennsylvania, Perelman School of MedicineRecruiting
  • Prisma HealthRecruiting
  • Carolina Urologic Research CenterRecruiting
  • Vanderbilt University Medical CenterRecruiting
  • Baylor Scott and White
  • Urology San Antonio, PA
  • Spokane Urology
  • Barwon Health, University Hospital Geelong
  • Royal Melbourne Hospital
  • Wollongong Private Hospital
  • National Cancer Center Hospital East
  • Nagoya University Hospital
  • Hirosaki University Hospital
  • Chugoku Rosai Hospital
  • Shinshu University Hospital
  • University of Tsukuba Hospital
  • Nara Medical University Hospital
  • The Jikei University Kashiwa Hospital
  • St. Marianna University Hospital
  • National Hospital Organization Kyoto Medical Center
  • Kagawa Rosai Hospital
  • Keio University Hospital
  • Okayama University Hospital
  • Osaka City University Hospital
  • Osaka Medical and Pharmaceutical University Hospital
  • Kitsato University Hospital
  • Saitama City Hospital
  • Sapporo Medical University Hospital
  • Shizuoka General Hospital
  • Keio University Hospital
  • Ehime University Hospital
  • Toyoma University Hospital
  • Wakayama Medical University Hospital
  • National Hospital Organization Yokohama Medical Center
  • Pusan National University Hospital
  • National Cancer Center
  • Pusan National University Yangsan Hospital
  • Chonnam National University Hwasun Hospital
  • Seoul National University Hospital
  • Korea University Anam Hospital
  • Severance Hospital
  • The Catholic University of Korea
  • Keelung Chang Gung Memorial Hospital
  • Keelung Chang Gung Memorial Hospital
  • China Medical University Hospital
  • National Taiwan University Hospital
  • Taipei Veterans General Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single Arm

Arm Description

Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease. CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments. Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter.

Outcomes

Primary Outcome Measures

Complete response rate in patients with carcinoma in situ (with or without concomitant high-grade Ta or T1 papillary disease)
Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.

Secondary Outcome Measures

Median Duration of response (DOR)
Median duration of response in patients with a CR or PR in subjects
Median progression free survival
Median duration of progression free survival of subjects
Time to tumor progression (TTP)
Median time until patient disease progression (PD) in subjects
Incidence of adverse events when CG0070 administered alone.
Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0.
Comparison of complete response in patients with persistent disease versus relapsed disease at baseline.
Percentage in CR

Full Information

First Posted
June 26, 2020
Last Updated
May 10, 2023
Sponsor
CG Oncology, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04452591
Brief Title
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Acronym
BOND-003
Official Title
A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 27, 2020 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CG Oncology, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease
Detailed Description
An open-label trial designed to evaluate CG0070 + DDM in patients with NMIBC who have failed prior BCG therapy. Single treatment arm that will enroll up to 110 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease BCG failure is defined as a persistent or recurrent disease within 12 months of completion of adequate BCG therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Muscular Invasive Bladder Cancer
Keywords
high-grade Ta papillary disease, high-grade T1 papillary disease, carcinoma in situ, Bacillus-Calmette-Guerin unresponsive

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single Arm
Arm Type
Experimental
Arm Description
Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease. CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments. Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter.
Intervention Type
Biological
Intervention Name(s)
CG0070
Intervention Description
Engineered Oncolytic Adenovirus
Intervention Type
Other
Intervention Name(s)
n-dodecyl-B-D-maltoside
Other Intervention Name(s)
DDM
Intervention Description
Transduction-enhancing agent.
Primary Outcome Measure Information:
Title
Complete response rate in patients with carcinoma in situ (with or without concomitant high-grade Ta or T1 papillary disease)
Description
Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Median Duration of response (DOR)
Description
Median duration of response in patients with a CR or PR in subjects
Time Frame
24 months
Title
Median progression free survival
Description
Median duration of progression free survival of subjects
Time Frame
24 months
Title
Time to tumor progression (TTP)
Description
Median time until patient disease progression (PD) in subjects
Time Frame
24 months
Title
Incidence of adverse events when CG0070 administered alone.
Description
Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0.
Time Frame
24 months
Title
Comparison of complete response in patients with persistent disease versus relapsed disease at baseline.
Description
Percentage in CR
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Have pathologically confirmed World Health Organization (WHO) grading system employed for tumor grading) high-risk NMIBC unresponsive to prior BCG therapy defined as: Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy Received prior adequate BCG therapy as defined as at least one of the following ("5+2" minimum exposure): At least five of six doses of an initial induction course (adequate induction) plus at least two of three doses of maintenance therapy, OR At least five of six doses of an initial induction course (adequate induction) plus at least two of six doses of a second induction course. Ineligible for radical cystectomy or refusal of radical cystectomy Adequate organ function Key Exclusion Criteria: Muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer Has known upper tract or prostatic urethra malignancy Has systemic anti-cancer therapy, including investigational agents, within 4 weeks of Baseline Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior organ transplant Prior treatment with adenovirus-based cancer therapy Clinically significant or active cardiac disease Active autoimmune disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
JoAnn Horn
Phone
516-456-1415
Email
joann.horn@CGoncology.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Burke, MD
Organizational Affiliation
CG Oncology, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Urology Centers of Alabama
City
Homewood
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
BCG Oncology
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85032
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Mayo Clinic Cancer Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clinical Trials Office All Mayo Clinic Locations
Phone
855-776-0015
First Name & Middle Initial & Last Name & Degree
Mark Tyson, MD
Facility Name
Arizona Institute of Urology
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Crystal Palencia
First Name & Middle Initial & Last Name & Degree
Jay Page, MD
Facility Name
University of California - Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Bereta
First Name & Middle Initial & Last Name & Degree
Edward Uchio, MD
Facility Name
American Institute of Research
City
Los Angeles
State/Province
California
ZIP/Postal Code
90017
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Skyline Urology - Sherman Oaks
City
Sherman Oaks
State/Province
California
ZIP/Postal Code
91411
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Skyline Urology - Torrance
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janet Kukreja
Facility Name
MedStar Hospital
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lambros Stamatakis
Facility Name
Mayo Clinic - Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Hendrix
First Name & Middle Initial & Last Name & Degree
Timothy Lyon, MD
Facility Name
Moffit Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rodger Li
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Misaki Mason
First Name & Middle Initial & Last Name & Degree
Shreyas Joshi, MD
Facility Name
University of Kansas
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eugene Lee, MD
Facility Name
Chesapeake Urology
City
Severna Park
State/Province
Maryland
ZIP/Postal Code
21076
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rian Dickstein
Facility Name
Mayo Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paras Shah
Facility Name
Mercy Medical Center
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gautam Agarwal
Facility Name
New Jersey Urology
City
Edison
State/Province
New Jersey
ZIP/Postal Code
08837
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haleema Hameed
First Name & Middle Initial & Last Name & Degree
Joshua Wein, MD
Facility Name
Our Lady of Lourdes
City
Binghamton
State/Province
New York
ZIP/Postal Code
13905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathleen McGinley
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
StonyBrook Cancer Center
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794-263
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Audrey Anderson
First Name & Middle Initial & Last Name & Degree
David Golumbos, MD
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Whitney Franz
First Name & Middle Initial & Last Name & Degree
Brant Inman, MD
Facility Name
Wake Forest University
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matvey Tsivian
Facility Name
University of Toledo
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43614
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smiddy
First Name & Middle Initial & Last Name & Degree
Firas G Petros, MD
Facility Name
University of Pennsylvania, Perelman School of Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanna Stambakio
First Name & Middle Initial & Last Name & Degree
Thomas Guzzo, MD
Facility Name
Prisma Health
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leesa Judd
First Name & Middle Initial & Last Name & Degree
Ryan Werntz, MD
Facility Name
Carolina Urologic Research Center
City
Myrtle Beach
State/Province
South Carolina
ZIP/Postal Code
29572
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ryan Sutton
First Name & Middle Initial & Last Name & Degree
Neal Shore, MD
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pamela Steele
First Name & Middle Initial & Last Name & Degree
Sam Chang, MD
Facility Name
Baylor Scott and White
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Urology San Antonio, PA
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Withdrawn
Facility Name
Spokane Urology
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Barwon Health, University Hospital Geelong
City
Geelong
Country
Australia
Individual Site Status
Active, not recruiting
Facility Name
Royal Melbourne Hospital
City
Melbourne
Country
Australia
Individual Site Status
Active, not recruiting
Facility Name
Wollongong Private Hospital
City
Wollongong
Country
Australia
Individual Site Status
Active, not recruiting
Facility Name
National Cancer Center Hospital East
City
Chiba
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Nagoya University Hospital
City
Fujita
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Hirosaki University Hospital
City
Hashimoto
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Chugoku Rosai Hospital
City
Hiroshima
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Shinshu University Hospital
City
Ishizuka
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
University of Tsukuba Hospital
City
Kandori
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Nara Medical University Hospital
City
Kashihara
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
The Jikei University Kashiwa Hospital
City
Kashiwa
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
St. Marianna University Hospital
City
Kikuchi
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
National Hospital Organization Kyoto Medical Center
City
Kyoto
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Kagawa Rosai Hospital
City
Marugame
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Keio University Hospital
City
Matsumoto
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Okayama University Hospital
City
Okayama
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Osaka City University Hospital
City
Osaka
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Osaka Medical and Pharmaceutical University Hospital
City
Osaka
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Kitsato University Hospital
City
Sagamihara
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Saitama City Hospital
City
Saitama
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Sapporo Medical University Hospital
City
Sapporo
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Shizuoka General Hospital
City
Shizuoka
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Keio University Hospital
City
Tokyo
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Ehime University Hospital
City
Toon
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Toyoma University Hospital
City
Toyoma
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Wakayama Medical University Hospital
City
Wakayama
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
National Hospital Organization Yokohama Medical Center
City
Yokohama
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Pusan National University Hospital
City
Busan
ZIP/Postal Code
49241
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
National Cancer Center
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Pusan National University Yangsan Hospital
City
Gyeongsang
ZIP/Postal Code
50612
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Chonnam National University Hwasun Hospital
City
Jeongnam
ZIP/Postal Code
58128
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Korea University Anam Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Severance Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
The Catholic University of Korea
City
Seoul
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Keelung Chang Gung Memorial Hospital
City
Keelung City
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Keelung Chang Gung Memorial Hospital
City
Keelung
ZIP/Postal Code
204
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Taipei Veterans General Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

We'll reach out to this number within 24 hrs